5-FLUOROURACIL (5-FU), METHYL-CCNU, AND VINCRISTINE IN TREATMENT OF ADVANCED COLORECTAL CANCER - PHASE-2 STUDY UTILIZING WEEKLY 5-FU

Google Scholar
  • 1 January 1976
    • journal article
    • research article
    • Vol. 60  (11) , 1597-1600
Abstract
A phase II trial of 5-fluorouracil (5-FU), methyl-CCNU [1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea] and vincristine (FMV) combination chemotherapy in advanced colorectal carcinoma was reported. Ten of 25 patients (40%) achieved an objective tumor regression after treatment with FMV chemotherapy. The main toxicities of FMV were hematologic and gastrointestinal. 5-FU was administered in a weekly rather than a loading dose schedule which allowed for sensitive adjustment of drug dosages according to hematologic toxicity. Only 10% of the patients (4 of 25) had a wbc [white blood cell] count < 2000 cells/mm3. FMV is significantly more active than 5-FU alone in the treatment of advanced colorectal cancer. This regimen does not significantly improve survival in responding patients.